CN1283785C - 利用转基因动物乳腺生产人促红细胞生成素的方法 - Google Patents
利用转基因动物乳腺生产人促红细胞生成素的方法 Download PDFInfo
- Publication number
- CN1283785C CN1283785C CN 02111745 CN02111745A CN1283785C CN 1283785 C CN1283785 C CN 1283785C CN 02111745 CN02111745 CN 02111745 CN 02111745 A CN02111745 A CN 02111745A CN 1283785 C CN1283785 C CN 1283785C
- Authority
- CN
- China
- Prior art keywords
- milk
- cow
- sphaeroprotein
- sequence
- human erythropoietin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 23
- 241000282414 Homo sapiens Species 0.000 title claims description 8
- 210000002264 animal mammary gland Anatomy 0.000 title claims description 4
- 108700019146 Transgenes Proteins 0.000 title 1
- 108010036027 erythrogenin Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 71
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims abstract description 41
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims abstract description 41
- 230000004927 fusion Effects 0.000 claims abstract description 39
- 230000009261 transgenic effect Effects 0.000 claims abstract description 31
- 210000005075 mammary gland Anatomy 0.000 claims abstract description 30
- 102000044890 human EPO Human genes 0.000 claims abstract description 26
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 108020005065 3' Flanking Region Proteins 0.000 claims abstract description 16
- 108020005029 5' Flanking Region Proteins 0.000 claims abstract description 16
- 108091026890 Coding region Proteins 0.000 claims abstract description 13
- 235000020247 cow milk Nutrition 0.000 claims description 71
- 241001465754 Metazoa Species 0.000 claims description 34
- 108700024394 Exon Proteins 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 241001494479 Pecora Species 0.000 claims description 13
- 235000013336 milk Nutrition 0.000 claims description 12
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000000520 microinjection Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 abstract description 44
- 102000003951 Erythropoietin Human genes 0.000 abstract description 43
- 229940105423 erythropoietin Drugs 0.000 abstract description 43
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract description 43
- 108020004414 DNA Proteins 0.000 abstract description 37
- 241000283707 Capra Species 0.000 abstract description 18
- 241000283690 Bos taurus Species 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 108010060630 Lactoglobulins Proteins 0.000 abstract 1
- 102000008192 Lactoglobulins Human genes 0.000 abstract 1
- 230000006651 lactation Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 235000020251 goat milk Nutrition 0.000 description 12
- 230000009182 swimming Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000010023 transfer printing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101150002621 EPO gene Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 1
- NJPMYXWVWQWCSR-ACZMJKKPSA-N Ala-Glu-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NJPMYXWVWQWCSR-ACZMJKKPSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- PHQXWZGXKAFWAZ-ZLIFDBKOSA-N Ala-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 PHQXWZGXKAFWAZ-ZLIFDBKOSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- PHHRSPBBQUFULD-UWVGGRQHSA-N Arg-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N PHHRSPBBQUFULD-UWVGGRQHSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 1
- RBOBTTLFPRSXKZ-BZSNNMDCSA-N Asn-Phe-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RBOBTTLFPRSXKZ-BZSNNMDCSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VUVKKXPCKILIBD-AVGNSLFASA-N Gln-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N VUVKKXPCKILIBD-AVGNSLFASA-N 0.000 description 1
- FGWRYRAVBVOHIB-XIRDDKMYSA-N Gln-Pro-Trp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O FGWRYRAVBVOHIB-XIRDDKMYSA-N 0.000 description 1
- UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 1
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 1
- COSBSYQVPSODFX-GUBZILKMSA-N Glu-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N COSBSYQVPSODFX-GUBZILKMSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- GVVKYKCOFMMTKZ-WHFBIAKZSA-N Gly-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CN GVVKYKCOFMMTKZ-WHFBIAKZSA-N 0.000 description 1
- XLFHCWHXKSFVIB-BQBZGAKWSA-N Gly-Gln-Gln Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLFHCWHXKSFVIB-BQBZGAKWSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- YTKOTXRIWQHSAZ-GUBZILKMSA-N His-Glu-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N YTKOTXRIWQHSAZ-GUBZILKMSA-N 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- CTHAJJYOHOBUDY-GHCJXIJMSA-N Ile-Cys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N CTHAJJYOHOBUDY-GHCJXIJMSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- FPFOYSCDUWTZBF-IHPCNDPISA-N Leu-Trp-Leu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H]([NH3+])CC(C)C)C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 FPFOYSCDUWTZBF-IHPCNDPISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- BMHIFARYXOJDLD-WPRPVWTQSA-N Met-Gly-Val Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O BMHIFARYXOJDLD-WPRPVWTQSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000920676 Ovis aries Erythropoietin Proteins 0.000 description 1
- ONPFOYPPPOHMNH-UVBJJODRSA-N Pro-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@@H]3CCCN3 ONPFOYPPPOHMNH-UVBJJODRSA-N 0.000 description 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 1
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 1
- KCNSGAMPBPYUAI-CIUDSAMLSA-N Ser-Leu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KCNSGAMPBPYUAI-CIUDSAMLSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 1
- ZZDYJFVIKVSUFA-WLTAIBSBSA-N Tyr-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ZZDYJFVIKVSUFA-WLTAIBSBSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 1
- NGXQOQNXSGOYOI-BQFCYCMXSA-N Val-Trp-Gln Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 NGXQOQNXSGOYOI-BQFCYCMXSA-N 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/102—Caprine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供了生产EPO的新方法,包括:利用牛(B.taurus)的乳球蛋白(BLG)5′侧翼序列、部分外显子内含子序列及3′侧翼序列为乳腺特异表达的调控序列,以人促红细胞生成素(EPO)全长基因组DNA为编码序列,构建融合基因BLG-EPO,该融合基因可以在催乳山羊乳腺中瞬时表达。以该融合基因显微注射山羊受精卵原核,获得了人促红细胞生成素乳腺特异高效表达的转基因山羊。
Description
技术领域
本发明涉及基因工程和转基因动物领域,具体地,本发明涉及一种调控外源基因(如人促红细胞生成素)在动物乳腺组织特异性表达的载体,以及在动物乳腺中特异性表达外源基因的方法。本发明还涉及生产人促红细胞生成素的新方法。
背景技术
促红细胞生成素(EPO)是一种多功能的糖蛋白,具有刺激红细胞增殖分化等作用,临床主要用于治疗肾性贫血,是一种有重要价值的医用蛋白。EPO的生产方法主要是通过微生物发酵,然而目前的生产工艺成本较高,设备投入需要较多的资金,且对环境的污染也较严重。
动物乳腺组织具有较强的合成蛋白的功能,如能利用转基因技术将外源基因特别是有重要医疗价值的基因如人促红细胞生成素基因,人生长激素基因等转入动物体内,就有可能生产出大量的药用蛋白。人体内的许多蛋白的生理活性与翻译后修饰有关,通过原核表达的蛋白通常因为缺少翻译后修饰而不具备生物活性。以真核细胞培养来表达这些蛋白需要较高的成本,以转基因动物来表达外源蛋白,其产物接近天然即具有较高的生物活性、表达量高而且成本底。
用显微注射的方法转入动物体内的基因,其在动物体内的基因组的整合及表达是随机的,如果外源基因产物具有较强的生物活性,外源基因的随机表达或异位表达就有可能造成转基因动物体的疾病甚至死亡。如促红细胞生成素的异位表达会引起高红细胞血症。迄今为止,本领域还没有通过乳腺反应器(转基因羊或牛的乳腺)来生产EPO的报道。
因此,本领域迫切需要开发新的成本低、污染小的生产EPO的新方法。
发明内容
本发明的目的就是提供一种成本低、污染小的生产促红细胞生成素的方法,即利用转基因动物乳腺生产人促红细胞生成素,从而在动物乳腺中大量表达人促红细胞生成素。
本发明的另一目的是提供具有乳腺组织特异性的有关的表达融合基因、高效表达外源基因的载体、乳腺特异性表达EPO的转基因动物。
在本发明的第一方面,提供了一种乳腺特异性表达融合基因,该融合基因从5′至3′依次包含以下元件:牛乳球蛋白的5′侧翼序列、人促红细胞生成素基因组DNA序列、和牛乳球蛋白3′侧翼序列。
在一优选例中,该融合基因从5′至3′依次包含以下元件:牛乳球蛋白的5′侧翼序列、外显子1非编码序列、人促红细胞生成素基因组DNA序列、牛乳球蛋白外显子1编码序列、牛乳球蛋白内含子1、牛乳球蛋白外显子2、牛乳球蛋白内含子2、牛乳球蛋白外显子3、牛乳球蛋白外显子6、牛乳球蛋白内含子6、牛乳球蛋白外显子7及牛乳球蛋白3′侧翼序列。
在一优选例中,所述的融合基因在牛乳球蛋白的5′侧翼序列及外显子1非编码序列与人促红细胞生成素基因组DNA序列之间还有接头序列;和/或在人促红细胞生成素基因组DNA序列与牛乳球蛋白外显子1编码序列之间还有接头序列。
在另一优选例中,所述的融合基因中的牛乳球蛋白的5′侧翼序列、外显子1非编码序列具有SEQ ID NO:1所示的核苷酸序列;
人促红细胞生成素基因组DNA序列具有SEQ ID NO:2所示的核苷酸序列;
牛乳球蛋白外显子1、牛乳球蛋白内含子1、牛乳球蛋白外显子2、牛乳球蛋白内含子2、牛乳球蛋白外显子3具有SEQ ID NO:3所示的核苷酸序列;
牛乳球蛋白外显子6、牛乳球蛋白内含子6、牛乳球蛋白外显子7及牛乳球蛋白3′侧翼序列具有SEQ ID NO:4所示的核苷酸序列。
在第二方面,本发明提供了一种产生转基因动物的方法,它包括步骤:
(a)将本发明上述的乳腺特异性表达融合基因,显微注射动物受精卵原核,制得基因组中整合有融合基因的受精卵;
(b)将步骤(a)中的基因组中整合有融合基因的受精卵发育成转基因动物,该动物在其乳腺中有人促红细胞生成素的特异表达。
较佳地,该动物选自下组:羊、牛。
在第三方面,本发明提供了一种生产人促红细胞生成素的方法,它包括步骤:
(3)培养用本发明上述方法制得的转基因动物,从动物乳腺分泌的乳汁中分离纯化出表达的人促红细胞生成素。
在第四方面,本发明提供了一种调控外源基因在动物乳腺中特异性表达的载体,该载体含有权利要求1所述的融合基因。
在第五方面,本发明提供了一种乳汁,它含有浓度10-100,000ug/ml的人促红细胞生成素。更佳地,所述的乳汁含有浓度50-50,000ug/ml的人促红细胞生成素。
附图说明
图1是BLG-EPO融合基因元件构成示意图。
图2是BLG-EPO融合基因构建流程图。
图3是BLG-EPO融合基因酶切图谱。其中各酶切位点下方的数字为各位点的相对位置。
图4是融合基因BLG-EPO羊基因组的整合检测。其中,P为阳性对照,N为阴性对照,73、132、134、138为整合检测阳性的羊编号。
图5显示了转基因羊促红细胞生成素乳腺表达的检测结果。其中图5A为蛋白质转移到硝酸纤维素膜后的全蛋白丽春红染色;图5B为对醋酸纤维素膜进行抗体杂交后显色结果。各泳道如下:泳道1为分子量标记;泳道2为EPO标准品(沈阳三生),分子量为34KD,上样量为30IU;泳道3、4、5分别为134号羊催乳后第3、2、1天羊奶样品,上样量为0.5ul;泳道6、7、8分别为138号羊催乳后第3、2、1天羊奶样品,上样量为0.5ul。
图6是MTT法检测EPO活性标准曲线。
图7显示了乳腺表达的促红细胞生成素氨基酸序列。斜体表示信号肽序列,黑体表示成熟肽序列。
具体实施方式
本发明首先发现,利用牛乳球蛋白的5′侧翼序列和牛乳球蛋白3′侧翼序列,可以有效地使外源基因在转基因动物的乳腺中特异性表达。在此基础上完成了本发明。
在本发明的优选例中,所使用的牛乳球蛋白的序列包括:从5′至3′依次包含以下元件:牛乳球蛋白的5′侧翼序列、外显子1非编码序列、牛乳球蛋白外显子1编码序列、牛乳球蛋白内含子1、牛乳球蛋白外显子2、牛乳球蛋白内含子2、牛乳球蛋白外显子3、牛乳球蛋白外显子6、牛乳球蛋白内含子6、牛乳球蛋白外显子7及牛乳球蛋白3′侧翼序列。其中,一种更优选的方式是在外显子1非编码序列和牛乳球蛋白外显子1编码序列之间插入外源基因。
当然,在外源基因(如EPO基因)与牛乳球蛋白基因之间还可含有接头序列,例如在牛乳球蛋白的5′侧翼序列及外显子1非编码序列与人促红细胞生成素基因组DNA序列之间还有接头序列A;和/或在人促红细胞生成素基因组DNA序列与牛乳球蛋白外显子1编码序列之间还有接头序列B。接头序列的作用主要是便于克隆操作。设计和选用各种接头序列在本领域的技术人员技能之内。在本发明的一个优选例中,所示的接头序列是:接头序列A是5′-ctcgagtcacc-3′(SEQ ID NO:15);该接头序列B是5′-ccatgtcgagt-3′(SEQ ID NO:16)。
本发明还提供了一种调控外源基因在动物乳腺组织特异性表达的载体。为了使外源基因(人促红细胞生成素)在动物乳腺中特异表达,本发明利用牛乳蛋白基因的乳腺特异表达调控元件构建了乳腺特异表达的载体。一种优选的载体包括牛乳球蛋白基因的5′侧翼序列,部分外显子和内含子序列,3′侧翼序列。位于5′侧翼序列下游的供外源基因插入的多克隆位点,以及供载体连同插入其上的外源基因在大肠杆菌中复制的pGEM-Teasy序列。
在本发明的一个实施例中,所构建的载体的具有如下序列元件:
一、包括了牛乳球蛋白基因(BLG)的5′调控序列(-1216~+45bp);
二、包含了牛乳球蛋白基因外显子1至外显子3(+48~+1878bp)、外显子6至外显子7(+4109~+4723)及3′侧翼序列(734bp)。
在本发明另一实施例中,还以该特异性表达载体为基础,构建了表达人促红细胞生成素的融合基因BLG-EPO,该融合基因的特点为:EPO全长编码序列基因组DNA 5′端以BstEII补平连于BLG的5′调控序列及外显子1非编码序列的下游,3′端以NcoI补平连于BLG外显子1编码序列至3′侧翼序列的上游。该融合基因的EPO基因组DNA位于转录起始位点的下游,紧邻BLG的5′-UTR,因而EPO能在BLG启动子作用下而转录,转录体为融合mRNA,其编码序列为EPO基因组DNA,而5′-UTR及3′-UTR来源于BLG和EPO。因EPO基因组DNA提供了终止密码,因而只有EPO蛋白被编码,而BLG不被翻译。
本发明的载体/融合基因所包含的调控序列含有乳腺特异表达的元件,能保证外源基因在乳腺特异表达。
在本发明的另一实施例中,将以此载体构建能在乳腺特异表达人促红细胞生成素的融合基因BLG-EPO转入动物时,从而在动物乳腺中大量表达人促红细胞生成素。
可用于本发明的转基因动物没有特别限制,可以是任何哺乳动物,较佳地,该动物选自下组:羊、牛、兔,更佳地选自下组:羊、牛。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,例如Sambrook等人,分子克隆:实验室手册(New York:ColdSpring Harbor Laboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。
实施例1 EPO乳腺表达载体的构建
该实施例的基因构建过程如图2所示,该基因构建物即为BLG-EPO融合基因,其中调控序列来源于牛BLG和EPO,编码序列来源于EPO。
pBLG-EPO的制备
1.各部分元件的来源
1)牛BLG5′侧翼序列和外显子1非编码序列部分
根据GENBANK X14710报道的序列设计并合成如下引物:5′-cggccgggggtctgctcc-3′(SEQ ID NO:5)和5′-ctcgagggctgcagctggggtcac-3′(SEQ IDNO:6),以牛基因组DNA为模板,用PCR法(94℃,5min;94℃,1min;60℃45s;72℃90s,30个循环)扩增BLG5′侧翼序列及外显子1非编码部分序列(SEQ ID NO:1)。PCR产物并克隆于pGEM-Teasy载体(Promega公司),得质粒pBLG5′。
2)牛BLG外显子1-3及外显子6-7和3′侧翼序列
根据GENBANK X14710报道的序列设计并合成如下引物:5′-ctcgagtagtgcctcctgcttgccctg-3′(SEQ ID NO:7)和5′-atcgatcttgaacaccgcagg-3′(SEQ ID NO:8),以牛基因组DNA为模板,通过PCR(94℃,5min;94℃,1min;58℃45s;72℃90s,30个循环)扩增出外显子1-3序列(SEQ ID NO:3)并将PCR扩增产物克隆于pGEM-Teasy载体得质粒pBLG 1-3。
根据GENBANK X14710报道的序列设计并合成如下引物:5′-atcgatgtgagcccctgccggcgc-3′(SEQ ID NO:9)和5′-gcatgccaggcctttctgtc-3′(SEQ IDNO:10),以牛基因组DNA为模板,通过PCR通过PCR(94℃,5min;94℃,60s;56℃60s;72℃90s,35个循环)扩增出BLG外显子6~7及3′侧翼序列(SEQ ID NO:4),并将PCR扩增产物克隆于pGEM-Teasy载体得质粒pBLG 6-3′。
3)以人基因组DNA为模板,采用如下引物:5′-atgagggcccccggtgtg-3′(SEQ IDNO:11)和5′-agtgtccatgggacaggctg-3′(SEQ ID NO:12),通过PCR法获得EPO全长编码序列基因组DNA及部分5′-UTR和3′-UTR序列(SEQ ID NO:2),并将其克隆入pGEM-Teasy载体,得质粒pEPO。
2.pBLG-EPO的构建
以ClaI和SalI双酶切pBLG6-3′回收外显子6-3′片段(约1350bp)将该片段连于pBLG1-3的ClaI和SalI位点得pBLG1-3′;以XhoI和SalI双酶切pBLG1-3′回收BLG1-3′片段(约3.1Kb)将该片段连于pBLG5′的XhoI和SalI位点得pBLG;以BstEII和NcoI双酶切pEPO回收EPO片段(约2.3KB)将该片段平端连于pBLG的XhoI位点得pBLG-EPO。(构建过程详见图2)。
pBLG-EPO乳腺特异表达融合基因的酶切图谱,参见图3。
在pBLG-EPO中,EPO与BLG5′接头及其邻近序列如下:
转录起始位点BLG5′-UTR接头序列EPO5′-UTRCCTCCACTCCCTGCAGAGCTCAGAAGCGTGACCCCAGCTGCAGCC
CTCGAGTCACCCGGCGCGCCCCAGGTCGCTGAGGGACCCCGGCCAGGCGCGGAG
ATG(SEQ ID NO:13)
起始密码子
EPO与BLG 3′接头及邻近序列如下:
EPO3′-UTR接头序列BLG3′-UTRTCGAGGGGCTCTCAGCTCAGCGCCAGCCTGTC
CCATGTCGAGTAGTGCCTCCTGCTTGCCCTGGCCCTCACTTGTGGCGC
参见图1,在人促红细胞生成素乳腺特异性表达载体pBLG-EPO或融合基因BLG-EPO中,各元件的功能如下:
阴影框部分为BLG的5′侧翼序列,该部分是BLG启动子,负责驱动外源基因的表达,保证外源基因表达是乳腺特异性的。→表示BLG5′非翻译区(5′-UTR),5′-UTR为外源基因翻译编码形成蛋白提供核糖体结合位点。其详细序列参见附图4和SEQ ID NO:1。
空心框部分为外源基因EPO全长编码序列。包括翻译起始密码及终止密码子。序列详见SEQ ID NO:2。
实心框部分为牛BLG外显子1至外显子3,外显子6~7和3′侧翼序列,其作用是提供转录终止信号及加Poly A信号。外显子部分向外源基因提供3′非翻译区,内含子部分及3′侧翼序列与乳腺特异性高效表达的调控有关,序列详见SEQID NO:3,以及SEQ ID NO:4。
人EPO的氨基酸序列如图7和SEQ ID NO:17所示。
实施例2 融合基因pBLG-EPO转基因山羊的制备
1.转基因用质粒DNA的制备
1)质粒pBLG-EPO转化大肠杆菌DH52,液体培养含pBLG-EPO质粒的DH52菌株,培养量根据需要可为100ml-1000ml,然后收集细菌,用快速抽提法或大规模抽提法制备pBLG-EPO(详细操作参考曼尼安蒂斯主编的分子克隆手册)。
提取的pBLG-EPO质粒用NotI酶切,琼脂糖凝胶电泳,用SephaglassBabndprep(pharmacia biotech)试剂盒回收纯化6.82Kb的片段备用。
2)用显微注射DNA稀释液将纯化后DNA稀释至2ug/ml,离心(12000rpm,30min),分装,即可作显微注射用。
2.制备转基因动物
将融合基因BLG-EPO通过显微注射的方法导入到奶山羊受精卵雄原核内,然后再移植到同步发情的受体山羊输卵管内,待其妊娠产仔。
实施例3.融合基因pBLG-EPO转基因山羊基因组整合的检测
1.样品处理
未转基因山羊和待测转基因山羊,按常规操作取羊耳(长度小于1厘米),-20℃保存备用。
2.检测方法
1)基因组DNA的快速抽提:,将羊耳置于1.5ml离心管中,加0.5ml的LysisBuffer(4M Urea power,10mM EDTA(pH8.0),0.5%Sarkosyl(Sigma L5125),0.1MTris-Cl(pH 8.0),0.2M NaCl),50μl的蛋白酶K(10mg/ml)置于55℃的杂交炉中振摇过夜。离心(14000rpm)5min,转移上清至一个干净的离心管中,加入1ml无水乙醇轻轻混合后强烈振摇,用Tip头轻轻挑起絮状DNA沉淀,用250-300μl的0.1×TE或双蒸水重悬DNA,吹打混匀,4℃保存。
2)酶切及电泳:取基因组DNA约10微克采用限制性内切酶EcoRI在37℃酶切12小时以上。酶切产物以1%琼脂糖凝胶电泳,1-2V/cm电压,电泳12小时以上。
变性及中和:加入变性液(1.5M NaCl 0.5M NaOH)使胶变性45分钟(轻摇),加入中和液(1.5M NaCl 0.5M Tris-Hcl(PH 8.0)轻摇中和45分钟(轻摇)
3)转膜:将尼龙膜均匀铺在胶上,上面铺3MM Waterman吸水纸3张,再铺纸塔(5-10厘米),压上重物,转膜18小时;用5×SSC冲洗膜以去除膜表面的凝胶碎片;在室温下晾干,80℃固定2小时。
4)探针制备:以EcoR I和Xho I双酶切质粒pBLG-EPO,回收3.5kb条带,产量应在500ng-1000ng间,采用随机引物标记试剂盒标记探针。
5)预杂交及杂交:转印膜在预杂交液(5×SSPE,5×Denhardt′s Solution,0.1%SDS,100μg/ml nonhomologous Salmon sperm blocking DNA,50%Formamide)中42℃预杂交4小时。将探针加入到预杂交液中,42℃杂交16小时。
6)洗膜压片洗片:采用Wash Solution(1×SSC,0.1%SDS)65℃洗涤1小时,重复此步骤,直到本底降到10以下。把洗后的膜用保险膜固定,暗室中放入X光片,-70℃保存两天。暗室中取出X光片,显影5分钟,定影15分钟,检查光片上所显示的结果,
2.检测结果
结果见附图4,泳道P为阳性对照:转基因构件BLG-EPO以EcoR I酶切;泳道N为阴性对照:未转基因山羊基因组DNA;其余泳道为待测转基因山羊基因组DNA。结果显示:转基因山羊(73、132、134、138)的基因组DNA中有BLG-EPO的整合。
实施例4.Western blot检测转基因山羊乳汁中人促红细胞生成素
1.样品处理
1)转基因奶山羊的人工诱乳:
选取奶山羊,每天肌肉注射苯甲酸雌二醇及黄体酮二次,每次剂量分别为2mg及20mg,共七天。然后分别于第8,10,12,14天肌肉注射利血平0.5mg。于第12天收集乳汁供EPO表达检测用
收集羊奶,脱脂处理(4000rpm,4℃,20min),加入等体积的TBS缓冲液(0.1mol/L Tris-碱,0.3mol/L NaCl,0.2mol/L EDTA,PH6.5),过0.22um滤膜除菌,样品中加入1×SDS凝胶加样缓冲液,于100℃煮沸3分钟,使蛋白变性。
2.检测方法
蛋白电泳:经处理样品进行SDS-PAGE凝胶电泳,积层胶:4%胶浓度,50V;分离胶:7.5%胶浓度,100V。
蛋白转印:电泳后在80mA电流下进行蛋白转印2小时,将蛋白转至硝酸纤维素膜上,以丽春红染色检测转印效果。转印膜用Tris-NaCl溶液(0.05mol/L Tris-碱,0.15mol/L NaCl,pH7.5)洗去结合在蛋白上的丽春红染料后用于杂交抗体。
抗体杂交:将转印膜放入平皿,加入适量封闭液(10%脱脂奶粉),以1∶3000的浓度加入第一抗体(鼠抗人促红细胞生成素抗体),于平缓摇动的摇床上室温杂交四小时;杂交结束,用Tris-NaCl溶液漂洗滤膜3次,每次10分钟;以1∶2000的浓度加入酶联二级抗体,室温杂交二小时;杂交结束,用Tris-NaCl溶液漂洗膜3次,每次10分钟,然后进行显色反应。
显色:在膜上加入适量底物(碱性磷酸酶用BCIP/NBT),暗反应约20分钟,就能看到蛋白条带。
3.检测结果
结果见附图5,图中泳道1为分子量标准物;泳道2为阳性对照EPO标准品(沈阳三生):;泳道3,4,5,6,7,8为待测转基因山羊乳蛋白。
结果显示:转基因山羊134、138(泳道3,4,5,6,7,8)的乳汁中有人促红细胞生成素的特异性条带显示。
实施例5.转基因山羊乳汁中人促红细胞生成素(EPO)体外生物活性测定(MTT法)
活细胞特别是增殖的细胞中能量代谢旺盛,利用线粒体能量代谢过程中产生的琥珀酸脱氢酶可将淡黄色的MTT还原为蓝紫色结晶沉积在细胞核周围,形成的结晶与增值的细胞数成正比。利用32D细胞对EPO的生长依赖特性,可检测培养液中的EPO活性。
1.实验材料:
1640培养液:按说明书配制,4度保存。
基础培养液:1640培养液添加10%的小牛血清,1*P/S,4度保存。
完全培养液:基础培养液添加EPO至终浓度1-2U/ml,4度保存。
PBS:NaCl 8g、KCl 0.2g、Na2HPO4、KH2PO40.24g加蒸馏水配成1000ml。121度15分钟灭菌。
噻唑蓝MTT溶液:用PBS配成5.0mg/ml的溶液,经0.22um滤器过滤除菌,4度避光保存。
裂解液:10%的SDS、0.01mol/mlHCl。
32D细胞培养物:32D细胞在完全培养液中培养24-48个小时用于EPO活性测定。
EPO标准品:沈阳三生益比奥3000U/ml,4℃保存。
2.实验步骤:
空白羊奶制备:
空白羊奶用针头滤器除菌过滤。用基础培养液稀释成10%的溶液。
样品溶液制备:
除菌过滤,羊奶样品用针头滤器过滤除菌,用基础培养液稀释成10%的溶液,按样品的含量用10%的空白羊奶稀释成不同浓度梯度的样品。
制备标准品样品稀释:
取益比奥用10%的空白羊奶配成12.8U/ml的溶液,然后用空白羊奶倍比稀释成12.8、6.4、3.2、1.6、0.8、0.4、0.2、0.1、0.05U/ml。
制备细胞悬液:
取足量的32D细胞培养物离心收集32D细胞,用基础培养液洗涤三次,重悬于基础培养液中计数配成40万细胞每毫升备用。在96孔板中按下表加入标准系列100ul,及样品100ul,每个3-4复孔
加入细胞悬液及培养:
每孔加入100ul细胞悬液,置37℃,5%CO2培养44小时(至2A-D存活细胞不足11A-D的10%)
加入MTT并培养:
酶孔加入10ulMTT溶液,37℃,5%CO2培养4小时
加入裂解液并保温:
酶孔加入100ul裂解液,37℃保温18-24小时
测定光密度值:
在酶标仪上比色,测定波长590nm(570-600,可选用参比波长630nm),记录测定结果。
3.结果
MTT法检测EPO活性标准曲线如图6所示。以标准系列浓度u/ml的对数对OD590作直线回归,计算样品EPO浓度,结果表明BLG-EPO整合羊132、134、138乳腺表达EPO分别达117U/ml、28000U/ml、19038U/ml乳汁。
MTT法检测EPO活性标准曲线的制定
EPOu/ml | OD590 | OD590 | OD590 | OD590 | log(EPO u/ml) | OD590平均值 | |
0.098 | 0.093 | 0.092 | 0.091 | 0.0935 | |||
0 | 0.553 | 0.579 | 0.584 | 0.587 | 0.57575 | ||
0 | 0.554 | 0.569 | 0.59 | 0.59 | 0.57575 | ||
0.025 | 0.578 | 0.621 | 0.635 | 0.627 | -1.602059991 | 0.61525 | |
0.05 | 0.654 | 0.683 | 0.71 | 0.668 | -1.301029996 | 0.67875 | |
0.1 | 0.722 | 0.812 | 0.837 | 0.854 | -1 | 0.80625 | |
0.2 | 0.905 | 1.047 | 1.043 | 1.088 | -0.698970004 | 1.02075 | |
0.4 | 1.022 | 1.197 | 1.198 | 1.2 | -0.397940009 | 1.15425 | |
0.8 | 1.423 | 1.455 | 1.377 | 1.507 | -0.096910013 | 1.4405 | |
1.6 | 1.639 | 1.231 | 1.555 | 1.529 | 0.204119983 | 1.4885 | |
3.2 | 1.31 | 1.553 | 1.505 | 1.657 | 0.505149978 | 1.50625 | |
整合羊132、134、138乳腺表达EPO活性的测定 | |||||||
山羊132 | |||||||
日期/稀释度 | OD590 | OD590 | OD590 | OD590 | 平均值 | EPO u/ml | EPOu/ml羊奶 |
20/3 500 | 0.995 | 1.022 | 1.056 | 1.069 | 1.0355 | 0.211777906 | 105.888953 |
21/3 500 | 1.003 | 1.093 | 1.041 | 1.041 | 1.0445 | 0.218956118 | 109.4780592 |
22/3 500 | 1.088 | 1.107 | 1.045 | 1.013 | 1.06325 | 0.234701749 | 117.3508746 |
山羊134 | |||||||
20/3 125000 | 1.113 | 1.013 | 1.092 | 0.995 | 1.05325 | 0.226168125 | 28271.01564 |
21/3 125000 | 0.999 | 1 | 1.015 | 1.01 | 1.006 | 0.189858529 | 23732.31609 |
22/3 125000 | 0.965 | 0.998 | 0.985 | 0.963 | 0.97775 | 0.170997668 | 21374.70852 |
山羊138 | |||||||
20/3 25000 | 1.053 | 1.029 | 1.054 | 0.976 | 1.028 | 0.205976158 | 5149.403954 |
21/31 25000 | 1.025 | 0.973 | 0.895 | 0.838 | 0.93275 | 0.14474648 | 18093.30996 |
22/31 25000 | 1.127 | 0.925 | 0.819 | 0.915 | 0.9465 | 0.152308727 | 19038.59081 |
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
序列表
<110>上海杰隆生物工程股份有限公司
<120>利用转基因动物乳腺生产人促红细胞生成素的方法
<130>022856
<160>17
<170>PatentIn version 3.1
<210>1
<211>1264
<212>DNA
<213>牛(B.taurus)
<400>1
cggccggggg tctgctcccg tgggtgggct ctttctggta cagtcaccaa cagtctctcc 60
gggaaggaaa ccagaggcca gagagcaagc cagagctagt ctaggagatc cctgagcctc 120
cacccaagat gccgaccagg ccagcgggcc ccctggaaag accctacagt ctaggggggg 180
aacaggagcc gacccgccag gcccccgcta tcaggagaca ccccaacctt gctcctgttc 240
ccctacccca gtacgcccac ccgacccctg agatgagtgg tttacttgct tagaatgtca 300
attgaaggct tttgtacccc ctttgccagt ggcacagggc acccacagcc cgttgggtac 360
tgatgcccat gtggactcag ccaggaggac tgtcctgcgc cctccctgct cgggccccct 420
ccatactcag cgacacaccc agcaccagca ttcccaccac tcctgaggtc tgaaggcagc 480
tcgctgtggt ctgagcggtg cggagggaag tgccctggga gatttaaaat gtgagaggtg 540
ggaggtggga ggttgggtcc tgtaggcctt cccatcccac gtgcctgcac ggagccctag 600
tgctactcag tcatgccccc gcagcagggg tcaggtcact ttcccatcct gggggttatt 660
atgactgttg tcattgttgt tgccattttt gctaccctaa ctgggtagcg ggtgcttgca 720
gagccctcga tactgaccag gttcccccct cggagctcga cctgaacccc atgtcaccct 780
cgccccagcc tgcagaggga gaggtgactg cagagatccc tttacccaag gccacagtca 840
catggtttgg aggagatggt gcccaaggca gaagccaccc tccaggacac acctgccccc 900
agtgctggct ctgacctgtc cttgtctaag aggctgaccc cagaagtgtt cctggcgctg 960
gcagccagcc tggacccaga gcctggacaa ccccctgcgc ccccacttct ggggcgtacc 1020
aggaaccgtc caggcccaga gggggccttc ccgcttggcc tcgaatggaa gaaggcctcc 1080
tattgtcctc gtagaggaag caaccccagg gcccaaggaa aggccagggg ggattcgggg 1140
aaccgcgtgg ctgggggccc ggcccgggct ggctggctgg ccctcctcct gtataaggcc 1200
ccgagcccgc tgtctcagcc ctccactccc tgcagagctc agaagcgtga ccccagctgc 1260
agcc 1264
<210>2
<211>2309
<212>DNA
<213>智人(Homo sapiens)
<400>2
cggcgcgccc caggtcgctg agggaccccg gccaggcgcg gagatggggg tgcacggtga 60
gtactcgcgg gctgggcgct cccgcccgcc cgggtccctg tttgagcggg gatttagcgc 120
cccggctatt ggccaggagg tggctgggtt caaggaccgg cgacttgtca aggaccccgg 180
aagggggagg ggggtggggc agcctccacg tgccagcggg gacttggggg agtccttggg 240
gatggcaaaa acctgacctg tgaaggggac acagtttggg ggttgagggg aagaaggttt 300
gggggttctg ctgtgccagt ggagaggaag ctgataagct gataacctgg gcgctggagc 360
caccacttat ctgccagagg ggaagcctct gtcacaccag gattgaagtt tggccggaga 420
agtggatgct ggtagctggg ggtggggtgt gcacacggca gcaggattga atgaaggcca 480
gggaggcagc acctgagtgc ttgcatggtt ggggacagga aggacgagct ggggcagaga 540
cgtggggatg aaggaagctg tccttccaca gccacccttc tccctccccg cctgactctc 600
agcctggcta tctgttctag aatgtcctgc ctggctgtgg cttctcctgt ccctgctgtc 660
gctccctctg ggcctcccag tcctgggcgc cccaccacgc ctcatctgtg acagccgagt 720
cctggagagg tacctcttgg aggccaagga ggccgagaat atcacggtga gaccccttcc 780
ccagcacatt ccacagaact cacgctcagg gcttcaggga actcctccca gatccaggaa 840
cctggcactt ggtttggggt ggagttggga agctagacac tgccccccta cataagaata 900
agtctggtgg ccccaaacca tacctggaaa ctaggcaagg agcaaagcca gcagatccta 960
cggcctgtgg gccagggcca gagccttcag ggacccttga ctccccgggc tgtgtgcatt 1020
tcagacgggc tgtgctgaac actgcagctt gaatgagaat atcactgtcc cagacaccaa 1080
agttaatttc tatgcctgga agaggatgga ggtgagttcc tttttttttt tttttccttt 1140
cttttggaga atctcatttg cgagcctgat tttggatgaa agggagaatg atcgagggaa 1200
aggtaaaatg gagcagcaga gatgaggctg cctgggcgca gaggctcacg tctataatcc 1260
caggctgaga tggccgagat gggagaattg cttgagccct ggagtttcag accaacctag 1320
gcagcatagt gagatccccc atctctacaa acatttaaaa aaattagtca ggtgaagtgg 1380
tgcatggtgg tagtcccaga tatttggaag gctgaggcgg gaggatcgct tgagcccagg 1440
aatttgaggc tgcagtgagc tgtgatcaca ccactgcact ccagcctcag tgacagagtg 1500
aggccctgtc tcaaaaaaga aaagaaaaaa gaaaaataat gagggctgta tggaatacat 1560
tcattattca ttcactcact cactcactca ttcattcatt cattcattca acaagtctta 1620
ttgcatacct tctgtttgct cagcttggtg cttggggctg ctgaggggca ggagggagag 1680
ggtgacatgg gtcagctgac tcccagagtc cactccctgt aggtcgggca gcaggccgta 1740
gaagtctggc agggcctggc cctgctgtcg gaagctgtcc tgcggggcca ggccctgttg 1800
gtcaactctt cccagccgtg ggagcccctg cagctgcatg tggataaagc cgtcagtggc 1860
cttcgcagcc tcaccactct gcttcgggct ctgggagccc aggtgagtag gagcggacac 1920
ttctgcttgc cctttctgta agaaggggag aagggtcttg ctaaggagta caggaactgt 1980
ccgtattcct tccctttctg tggcactgca gcgacctcct gttttctcct tggcagaagg 2040
aagccatctc ccctccagat gcggcctcag ctgctccact ccgaacaatc actgctgaca 2100
ctttccgcaa actcttccga gtctactcca atttcctccg gggaaagctg aagctgtaca 2160
caggggaggc ctgcaggaca ggggacagat gaccaggtgt gtccacctgg gcatatccac 2220
cacctccctc accaacattg cttgtgccac accctccccc gccactcctg aaccccgtcg 2280
aggggctctc agctcagcgc cagcctgtc 2309
<210>3
<211>1832
<212>DNA
<213>牛(B.taurus)
<400>3
agtgcctcct gcttgccctg gccctcactt gtggcgccca ggccctcatt gtcacccaga 60
ccatgaaggg cctggatatc cagaaggttc gagggtgccc gggtgggtgg tgagttgcag 120
ggcaggcagg ggagctgggc ctcagagacc aagggaggct gtgacgtctg ggattcccat 180
cagtcagcta gagccgcctg acaaatcgcc cgccagggca gcttcaacca ggcgtttagt 240
gtcttgcatt ctggaggctg gaagcctgca atccgggcat cggcccagct ggcttctcct 300
gcggccactc tccggggagc agacagccat cttctccctg tgtcctttgc gtgccctggt 360
ttcctcttcc tgtgaggtca ccaggcctgc tggatccacg cccgcccaca cagcctcacg 420
taacctttgt catctcttta aaggccgtgt ctccagtcct gtgttgaggt tctgggggtt 480
aatgggacac agttcagccc ctaaaagagt cgctctgccc ctcaaatttt ccccacctcc 540
agctatgtct ccccaagatc caaatgttgc cacgtgtgcg ggggctcatc tgggtccctc 600
tttgggctca gagtgagtct ggggagagca ttcctcaggg tgccgagttg gggggagcat 660
ctcagggctg cccaggccag ggtgggacag agagcccact gtggggctgg gggccccttc 720
ccgcccctgg agtgcagctc aaggtccctc cccaggtggc ggggacttgg tactccttgg 780
ccatggcggc cagcgacatc tccctgctgg acgcccagag tgcccccctg agagtgtatg 840
tggaggagct gaagcccacc cctgagggcg acctggagat cctgctgcag aaatggtggg 900
cgtccccccc aaaaaaagca tggaaccccc actccccagg gatatggacc cccccggggt 960
ggggtgcagg agggaccagg gccccagggc tggggaacgg ggcttggagt ttcctggtac 1020
ccctggaggt ccacccaagg ctgcttatcc agggctttct ctttcttttt ttcccccaac 1080
ttttattaat ttgatgcttc agaacatcat caagcaaatg aacacaaaac atcattttcg 1140
ttaacttgga aggggagata aaatccactg aagtggaaat gcataggaaa gatacataca 1200
gtaaggcagg tattctgaat tcgctgttag tttgaggatt acaaatgcac ttgagcaaca 1260
gagagacgtt ttcattattt ctggtctgaa cagctcagta tctaaaatga acaagatgtc 1320
atggagacaa agccggcggg ggagaggccc gtgtgaaggc cgctgggcgg ctgcagacct 1380
gggtcctcgg ggcccaggca gttcccacta ccagccctgt ccaccctcag acgggggtca 1440
gagtgcagga gagagctggg tgggtgtggg ggcagagatg gggacctgaa ccccaggact 1500
gccttttggg gtgcctgtgg tcaaggctct ccccaacctt ttctccctgg ctccatctga 1560
cttctcctgg cccatccacc cggtcacctg tggccccaga ggtgacagtg agtgcagcca 1620
aggccggttg gccagccggc cccctatgcc cacgccaccc gcctccagcc cctcctgggg 1680
ccgccttctg cccctggccc tcagttcatc ctgatgaaaa tggtccatgc ccgtggctca 1740
gaaagcagct gtctttcagg gagaacggtg agtgtgctca gaagaagatc attgcagaaa 1800
aaaccaagat ccctgcggtg ttcaagatcg at 1832
<210>4
<211>1347
<212>DNA
<213>牛(B.taurus)
<400>4
gtgagcccct gccggcgcct ctggggtaag ctgcctgccc tgccccacgt cctgggcaca 60
cacatggggt aggggttctt gattgggccc gggagccccc attaggccct ggggtccccc 120
cgtaggaatg gctggaagct ggggtccttc ctggagacta cagagccggc tggccacatg 180
ctcgctcttg tggggtgacc tgtgtcctgg cctcactcac acgctgatct cctccacctc 240
cttcctggca gacctaaggg ccaaggtgga ggctcaggaa gtggacacct aagggggagg 300
ctaggggggt ccttctccca aggaggggcc gtcctgaatc cccagccacg gacaggctgg 360
caagggtctg gcaggtaccc caggaatcac aggggagccc catgtccatt tcagagcccg 420
ggagccttgg cccctctggg gacagacgat gtcatccccg cctgccccat caggggacca 480
ggaggaaccg ggaccacatt cacccctcct gggacccagg cccctccagg cccctcctgg 540
ggcctcctgc ttggggccgc tcctccctca gcaataaagg cgtaaacctg tgctctccct 600
tctgagtctt tcctggatga tgggccgggg gtggagaagg cccgggacag ggtggggagt 660
ggtctggctc agaggatgat ggtagggctg ggatccaggg cgtctgcatt acagtcttga 720
gacatctggg ggcccacaca catcactacg gctctttgaa actttcagga accaggtagg 780
gagtcggcag agacatctgc cagttaactt ggagtgttca gtcaacaccc aaactcgaca 840
aaggacagga agtggaaaat ggctgtctct tagtctaata aatattgata tgaaagctca 900
agttgctcat ggatcaaatt atgccttttt atgaatccag ccactacagt cggtatcaaa 960
cttcatgtac tcaaaacgca ctgatctttt ctgtgctaaa atgaaataaa gagatttccc 1020
caagatacag gtgctgggca aaagaggtca cggttggaag gggacttgtt ctgcacacac 1080
agcaaggaga tccagccagt ccatcctaaa ggagatcagt cctgggtgtt cattggaggg 1140
actgatgttg aagctgaaac tccaatactt tggccacatg atgcggagag ctgactcatt 1200
tgaaaagacc ctgatactgg gaaagattga gggcaggagg agaaggggat gacagaggat 1260
gagatggttg gatggcatca ccgacaaaat ggacatgggt ttgggtggac tccaggagtt 1320
ggtgatggac agaaaggcct ggcatgc 1347
<210>5
<211>18
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>5
cggccggggg tctgctcc 18
<210>6
<211>24
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>6
ctcgagggct gcagctgggg tcac 24
<210>7
<211>27
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>7
ctcgagtagt gcctcctgct tgccctg 27
<210>8
<211>21
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>8
atcgatcttg aacaccgcag g 21
<210>9
<211>24
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>9
atcgatgtga gcccctgccg gcgc 24
<210>10
<211>20
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>10
gcatgccagg cctttctgtc 20
<210>11
<211>18
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>11
atgagggccc ccggtgtg 18
<210>12
<211>20
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>引物
<400>12
agtgtccatg ggacaggctg 20
<210>13
<211>102
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>EPO与BLG5’接头及其邻近序列
<400>13
cctccactcc ctgcagagct cagaagcgtg accccagctg cagccctcga gtcacccggc 60
gcgccccagg tcgctgaggg accccggcca ggcgcggaga tg 102
<210>14
<211>80
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>EPO与BLG 3’接头及邻近序列
<400>14
tcgaggggct ctcagctcag cgccagcctg tcccatgtcg agtagtgcct cctgcttgcc 60
ctggccctca cttgtggcgc 80
<210>15
<211>11
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>接头序列
<400>15
ctcgagtcac c 11
<210>16
<211>11
<212>DNA
<213>人工序列
<220>
<221>misc_feature
<223>接头序列
<400>16
ccatgtcgag t 11
<210>17
<211>193
<212>PRT
<213>智人(Homo sapiens)
<220>
<221>misc_feature
<222>(1)..(27)
<223>信号肽
<400>17
Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
1 5 10 15
Leu Ser Leu Pro Leu Gly Leu Pro Val Leu Gly Ala Pro Pro Arg Leu
20 25 30
Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala Lys Glu
35 40 45
Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His Cys Ser Leu Asn Glu
50 55 60
Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg
65 70 75 80
Met Glu Val Gly Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu
85 90 95
Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser
100 105 110
Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp Lys Ala Val Ser Gly
115 120 125
Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Lys Glu
130 135 140
Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile
145 150 155 160
Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu
165 170 175
Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Gly Asp
180 185 190
Arg
Claims (11)
1.一种乳腺特异性表达融合基因,其特征在于,该融合基因从5′至3′依次包含以下元件:牛乳球蛋白的5′侧翼序列、人促红细胞生成素基因组DNA序列、和牛乳球蛋白3′侧翼序列。
2.如权利要求1所述的融合基因,其特征在于,该融合基因从5′至3′依次包含以下元件:牛乳球蛋白的5′侧翼序列、外显子1非编码序列、人促红细胞生成素基因组DNA序列、牛乳球蛋白外显子1编码序列、牛乳球蛋白内含子1、牛乳球蛋白外显子2、牛乳球蛋白内含子2、牛乳球蛋白外显子3、牛乳球蛋白外显子6、牛乳球蛋白内含子6、牛乳球蛋白外显子7及牛乳球蛋白3′侧翼序列。
3.如权利要求2所述的融合基因,其特征在于,在牛乳球蛋白的5′侧翼序列及外显子1非编码序列与人促红细胞生成素基因组DNA序列之间还有接头序列;和/或在人促红细胞生成素基因组DNA序列与牛乳球蛋白外显子1编码序列之间还有接头序列。
4.如权利要求3所述的融合基因,其特征在于,在牛乳球蛋白的5′侧翼序列及外显子1非编码序列与人促红细胞生成素基因组DNA序列之间的接头序列是CTCGAGTCACC;而在人促红细胞生成素基因组DNA序列与牛乳球蛋白外显子1编码序列之间的接头序列是CCATGTCGAGT。
5.如权利要求2所述的融合基因,其特征在于,牛乳球蛋白的5′侧翼序列、外显子1非编码序列具有SEQ ID NO:1所示的核苷酸序列;
人促红细胞生成素基因组DNA序列具有SEQ ID NO:2所示的核苷酸序列;
牛乳球蛋白外显子1编码序列、牛乳球蛋白内含子1、牛乳球蛋白外显子2、牛乳球蛋白内含子2、牛乳球蛋白外显子3具有SEQ ID NO:3所示的核苷酸序列;
牛乳球蛋白外显子6、牛乳球蛋白内含子6、牛乳球蛋白外显子7及牛乳球蛋白3′侧翼序列具有SEQ ID NO:4所示的核苷酸序列。
6.一种产生转基因动物的方法,其特征在于,它包括步骤:
(1)将权利要求1所述的乳腺特异性表达融合基因,显微注射动物受精卵原核,制得基因组中整合有融合基因的受精卵;
(2)将步骤(1)中的基因组中整合有融合基因的受精卵发育成转基因动物,该动物在其乳腺中有人促红细胞生成素的特异表达。
7.如权利要求6所述的方法,其特征在于,该动物选自下组:羊、牛。
8.一种生产人促红细胞生成素的方法,其特征在于,它包括步骤:
(3)培养用权利要求6所述方法制得的转基因动物,从动物乳腺分泌的乳汁中分离纯化出表达的人促红细胞生成素。
9.如权利要求8所述的方法,其特征在于,所述的乳汁含有浓度10-5000ug/ml的人促红细胞生成素。
10.如权利要求9所述的方法,其特征在于,所述的乳汁含有浓度50-1000ug/ml的人促红细胞生成素。
11.一种调控外源基因在动物乳腺中特异性表达的载体,其特征在于,该载体含有权利要求1所述的融合基因。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02111745 CN1283785C (zh) | 2002-05-20 | 2002-05-20 | 利用转基因动物乳腺生产人促红细胞生成素的方法 |
AU2002344518A AU2002344518A1 (en) | 2002-05-20 | 2002-10-21 | A method for producing transgenic animal mammary glands secreting human erythropoietin (epo). |
PCT/CN2002/000736 WO2003097818A1 (fr) | 2002-05-20 | 2002-10-21 | Procede de production de glandes mammaires d'animal transgenique secretant de l'erythropoietine humaine (epo) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02111745 CN1283785C (zh) | 2002-05-20 | 2002-05-20 | 利用转基因动物乳腺生产人促红细胞生成素的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1459457A CN1459457A (zh) | 2003-12-03 |
CN1283785C true CN1283785C (zh) | 2006-11-08 |
Family
ID=29426367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02111745 Expired - Fee Related CN1283785C (zh) | 2002-05-20 | 2002-05-20 | 利用转基因动物乳腺生产人促红细胞生成素的方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1283785C (zh) |
AU (1) | AU2002344518A1 (zh) |
WO (1) | WO2003097818A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100205680A1 (en) * | 2007-08-08 | 2010-08-12 | Jin Hoi Kim | Mammary gland- specific human erytheropoietin expression vector, transgenic animal and method for producing human erythropoietin using same |
US9738694B2 (en) | 2008-06-30 | 2017-08-22 | Cho-A Pharm. Co., Ltd. | Gene of porcine alpha-s1 casein, a promoter of the same and use thereof |
AU2008359017B2 (en) | 2008-06-30 | 2013-01-17 | Cho-A Pharm Co., Ltd. | A gene of porcine beta-casein, a promoter of the same and the use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5959171A (en) * | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
CA2382741A1 (en) * | 1999-10-14 | 2001-04-19 | Genzyme Transgenics Corporation | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
KR100358754B1 (ko) * | 2000-02-14 | 2002-11-07 | 대한민국 | 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지 |
-
2002
- 2002-05-20 CN CN 02111745 patent/CN1283785C/zh not_active Expired - Fee Related
- 2002-10-21 WO PCT/CN2002/000736 patent/WO2003097818A1/zh not_active Application Discontinuation
- 2002-10-21 AU AU2002344518A patent/AU2002344518A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003097818A1 (fr) | 2003-11-27 |
AU2002344518A1 (en) | 2003-12-02 |
CN1459457A (zh) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1079433C (zh) | 在转基因动物中生产纤维蛋白原 | |
CN1871252A (zh) | 在转基因哺乳动物奶中生产融合蛋白的方法 | |
CN1230991A (zh) | 仓鼠EF-1α转录调节DNA | |
CN1086262A (zh) | 新的dna序列 | |
CN1639333A (zh) | 利用基因重组蚕生产生理活性蛋白质的方法 | |
CN1195859C (zh) | 修饰化人源粒细胞-集落刺激因子及其制备方法 | |
CN1261589C (zh) | Aβ-肽的筛选方法 | |
CN1516734A (zh) | 生产人胶原的转化蚕 | |
CN1283785C (zh) | 利用转基因动物乳腺生产人促红细胞生成素的方法 | |
CN1826350A (zh) | 非糖基化人甲胎蛋白、制备方法及其应用 | |
CN1944645A (zh) | 利用乳腺生物反应器制备重组人的抗凝血酶ⅲ蛋白的方法 | |
CN1602359A (zh) | 靶向性载体的制备方法及其应用 | |
CN1289523C (zh) | 水稻钾、钠离子转运基因及其应用 | |
CN1520459A (zh) | 突变体的制造方法 | |
CN1774507A (zh) | 指导目的多肽在鳞翅目昆虫后产丝腺中表达的核酸及其应用 | |
CN1157635A (zh) | α-乳清蛋白基因构建物 | |
CN100339479C (zh) | 参与油菜素类固醇合成的基因 | |
CN1705743A (zh) | 猪uroplakinⅡ启动子和使用所述启动子生产有用蛋白质的方法 | |
CN100344759C (zh) | 小麦脱水应答转录因子DREB基因cDNA序列 | |
CN1566146A (zh) | 水稻茎杆伸长基因及其编码蛋白和用途 | |
CN1904056A (zh) | 含有VEGFR的Truncated Soluble cDNA的重组腺相关病毒及含有上述成份的基因治疗剂 | |
CN1163604C (zh) | 减毒水痘病毒冈株的基因62和利用基因62的减毒水痘活疫苗用病毒株的鉴定方法 | |
CN1229493C (zh) | 携带人原癌基因的哺乳动物癌细胞和转基因哺乳动物以及利用上述原癌基因的癌症诊断试剂盒 | |
CN1211484C (zh) | 提高基因表达水平的dna片段 | |
CN1817900A (zh) | 一种调控植物落粒性的转录因子及其编码基因与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061108 Termination date: 20180520 |
|
CF01 | Termination of patent right due to non-payment of annual fee |